Phathom Pharmaceuticals, Inc. (PHAT) stock declined over -1.19%, trading at $7.89 on NASDAQ, down from the previous close of $7.99. The stock opened at $7.98, fluctuating between $7.81 and $8.25 in the recent session.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Employees | 452 |
Beta | 0.72 |
Sales or Revenue | $682.00K |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) stock price is $7.89 in the last trading session. During the trading session, PHAT stock reached the peak price of $8.25 while $7.81 was the lowest point it dropped to. The percentage change in PHAT stock occurred in the recent session was -1.19% while the dollar amount for the price change in PHAT stock was -$0.10.
The NASDAQ listed PHAT is part of Biotechnology industry that operates in the broader Healthcare sector. Phathom Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Azmi Nabulsi M.D., M.P.H.
Co-Founder & Chief Operating Officer
Mr. Anthony J. Guzzo
Chief Accounting Officer
Mr. Lawrence Miller Esq., J.D.
Gen. Counsel & Sec.
Dr. Eckhard Leifke M.D., Ph.D.
Chief Medical Officer
Ms. Terrie J. Curran
Pres, Chief Executive Officer & Director
Ms. Molly Henderson CPA, MBA
Chief Financial & Bus. Officer
Mr. Joseph Hand J.D.
Chief Admin. Officer
Mr. Tom Harris
Chief Devel. Sciences Officer
PHAT's closing price is 30.09% higher than its 52-week low of $6.07 where as its distance from 52-week high of $19.71 is -59.97%.
Number of PHAT employees currently stands at 452.
Official Website of PHAT is: https://www.phathompharma.com
PHAT could be contacted at phone 877 742 8466 and can also be accessed through its website. PHAT operates from 100 Campus Drive, Florham Park, NJ 07932, United States.
PHAT stock volume for the day was 995.13K shares. The average number of PHAT shares traded daily for last 3 months was 1.33M.
The market value of PHAT currently stands at $539.50M with its latest stock price at $7.89 and 68.38M of its shares outstanding.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com